T1	Participants 103 144	neoadjuvant chemotherapy and trastuzumab.
T2	Participants 266 342	patients with large or locally advanced HER2-positive (HER2+) breast cancers
T3	Participants 793 967	27 HER2+ breast cancer patients enrolled in a preoperative clinical trial using trastuzumab, nab-paclitaxel and carboplatin combination therapy (BrUOG BR-211B (NCT00617942)).
T4	Participants 1264 1286	18Â weeks of treatment,
